{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:12:01Z","timestamp":1792023121572,"version":"4.4.0"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"UCB Pharma, Brussels, Belgium"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,11,29]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate psychometric performance of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) total and individual item scores in patients with psoriatic arthritis (PsA) and to estimate score change thresholds and scores corresponding to different levels of symptom\/impact severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data up to week 16 from 1252 patients with active PsA enrolled in two randomised controlled trials of bimekizumab (BE OPTIMAL (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03895203\">NCT03895203<\/jats:ext-link>) and BE COMPLETE (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03896581\">NCT03896581<\/jats:ext-link>)) were used to assess construct validity (correlations with other patient-reported outcomes), known-groups validity (based on Minimal Disease Activity index, Disease Activity Index for Psoriatic Arthritis and Psoriatic Arthritis Disease Activity Score), reliability (Cronbach\u2019s alpha and intraclass correlation coefficients (ICCs)) and responsiveness (sensitivity to change). Clinically meaningful within-patient improvement thresholds were estimated by anchor-based and distribution-based analyses, and symptom\/impact severity thresholds were estimated by receiver operating characteristic curve analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean (SD) PsAID-12 total score at baseline was 4.19 (1.94). PsAID-12 scores demonstrated good convergent validity and good known-groups validity. Internal consistency reliability (Cronbach\u2019s alpha 0.95) and test\u2013retest reliability (ICC \u2265 0.70) were also good. Responsiveness was acceptable (correlations \u22650.30 for most scores). Improvement thresholds were estimated at 1.5\u20132 points for the PsAID-12 total score and 2 or 3 points for item scores. Thresholds for different levels of symptom\/impact severity could be derived for most PsAID-12 items.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The PsAID-12 demonstrated robust psychometric properties in a large sample of patients with active PsA, supporting its use as a fit-for-purpose patient-reported outcome in this population. Furthermore, thresholds for score interpretation were derived.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003548","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T23:00:10Z","timestamp":1706742010000},"page":"e003548","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03895203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03896581","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03895203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03896581","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"first","affiliation":[{"name":"INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Sorbonne Universit\u00e9, Paris, France"},{"name":"Rheumatology Department, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-8567","authenticated-orcid":false,"given":"Ana-Maria","family":"Orbai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, John Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5255-2777","authenticated-orcid":false,"given":"Christopher G","family":"Pelligra","sequence":"additional","affiliation":[{"name":"Evidera, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Ciaravino","sequence":"additional","affiliation":[{"name":"UCB Pharma, Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ink","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB Pharma, Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[{"name":"UCB Pharma, Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-6354","authenticated-orcid":false,"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[{"name":"Patient Research Partner, Stichting Tools, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"2025100518500764000_10.1.e003548.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105534"},{"key":"2025100518500764000_10.1.e003548.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025100518500764000_10.1.e003548.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-020-01422-z","article-title":"Results of a global, patient-based survey assessing the impact of Psoriatic arthritis discussed in the context of the Psoriatic arthritis impact of disease (Psaid) questionnaire","volume":"18","author":"Coates","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2025100518500764000_10.1.e003548.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"2025100518500764000_10.1.e003548.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181077"},{"key":"2025100518500764000_10.1.e003548.6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/TCRM.S101619","article-title":"The Psoriatic arthritis impact of disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version","volume":"12","author":"Salaffi","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"2025100518500764000_10.1.e003548.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160924"},{"key":"2025100518500764000_10.1.e003548.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1277-1","article-title":"Minimal disease activity and impact of disease in Psoriatic arthritis: a Spanish cross-sectional multicenter study","volume":"19","author":"Queiro","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025100518500764000_10.1.e003548.9","article-title":"Longitudinal construct validity of the Psaid individual items: can we eliminate other questionnaires if using the Psaid?","volume":"70","author":"Walsh","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025100518500764000_10.1.e003548.10","doi-asserted-by":"crossref","unstructured":"da Cruz Ribeiro e Souza E , da Silva Carneiro SC , Yazbek MA , et al . Validation and clinical Interpretability of Psaid - Psoriatic arthritis impact of disease. Adv Rheumatol 2020;60. doi:10.1186\/s42358-020-00149-1","DOI":"10.1186\/s42358-020-00149-1"},{"key":"2025100518500764000_10.1.e003548.11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001321","article-title":"Patient\u2019s experience of Psoriatic arthritis: a conceptual model based on qualitative interviews","volume":"6","author":"Ogdie","year":"2020","journal-title":"RMD Open"},{"key":"2025100518500764000_10.1.e003548.12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001170","article-title":"Assessment of the patient acceptable symptom state (PASS) in Psoriatic arthritis: association with disease activity and quality of life indices","volume":"6","author":"Lubrano","year":"2020","journal-title":"RMD Open"},{"key":"2025100518500764000_10.1.e003548.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211996"},{"key":"2025100518500764000_10.1.e003548.14","unstructured":"FDA . Guidance for industry. patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available: https:\/\/www.fda.gov\/media\/77832\/download [Accessed 10 Nov 2022]."},{"key":"2025100518500764000_10.1.e003548.15","unstructured":"FDA . Patient-focused drug development guidance public workshop. methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. 2018. Available: https:\/\/www.fda.gov\/media\/116277\/download"},{"key":"2025100518500764000_10.1.e003548.16","unstructured":"FDA . Patient-focused drug development guidance public workshop. incorporating clinical outcome assessments into endpoints for regulatory decision-making. 2019. Available: https:\/\/www.fda.gov\/media\/132505\/download"},{"key":"2025100518500764000_10.1.e003548.17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with Psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled","volume":"401","author":"McInnes","year":"2023","journal-title":"The Lancet"},{"key":"2025100518500764000_10.1.e003548.18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active Psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u0391 inhibitors: a randomised, double-blind","volume":"401","author":"Merola","year":"2023","journal-title":"The Lancet"},{"key":"2025100518500764000_10.1.e003548.19","unstructured":"The EULAR Psoriatic Arthritis Impact of Disease: PsAID12 for clinical practice, Available: http:\/\/pitie-salpetriere.aphp.fr\/psaid\/questionnaire.php [Accessed 24 Apr 2023]."},{"key":"2025100518500764000_10.1.e003548.20","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9%3C1564::AID-ART6%3E3.0.CO;2-M"},{"key":"2025100518500764000_10.1.e003548.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"2025100518500764000_10.1.e003548.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.21084"},{"key":"2025100518500764000_10.1.e003548.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006296"},{"key":"2025100518500764000_10.1.e003548.24","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-019-0125-2","article-title":"Content validity and Psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with Psoriatic arthritis","volume":"3","author":"Cella","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"2025100518500764000_10.1.e003548.25","unstructured":"Mark EM . User\u2019s Manual for the SF-36v2 Health Survey 3rd edition. Lincoln, RI: QualityMetric, 2011."},{"key":"2025100518500764000_10.1.e003548.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025100518500764000_10.1.e003548.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"2025100518500764000_10.1.e003548.28","first-page":"S64","article-title":"Measures of Psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander\/Newcastle Enthesitis index (MEI), Leeds Enthesitis index (LEI), Spondyloarthritis research consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis score (MASES), Leeds Dactylitis index (LDI), patient global for Psoriatic arthritis, Dermatology life quality index (DLQI), Psoriatic arthritis quality of life (Psaqol), functional assessment of chronic illness therapy-fatigue (FACIT-F), Psoriatic arthritis response criteria (Psarc), Psoriatic arthritis joint activity index (Psajai), disease activity in Psoriatic arthritis (DAPSA), and composite Psoriatic disease activity index (CPDAI)","volume":"63 Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025100518500764000_10.1.e003548.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025100518500764000_10.1.e003548.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa030"},{"key":"2025100518500764000_10.1.e003548.31","unstructured":"Cohen J . Statistical Power Analysis for the Behavioral Sciences 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988."},{"key":"2025100518500764000_10.1.e003548.32","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1773-y"},{"key":"2025100518500764000_10.1.e003548.33","unstructured":"Nunnally JC , Bernstein IH . Psychometric theory 3rd edition. New York: McGraw-Hill, 1994."},{"key":"2025100518500764000_10.1.e003548.34","doi-asserted-by":"publisher","DOI":"10.1007\/BF02310555"},{"key":"2025100518500764000_10.1.e003548.35","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015291021312"},{"key":"2025100518500764000_10.1.e003548.36","unstructured":"Cappelleri JC . Patient-reported outcomes: measurement, implementation and interpretation. Boca Raton, FL: CRC Press\/Taylor & Francis Group, 2014."},{"key":"2025100518500764000_10.1.e003548.37","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050663"},{"key":"2025100518500764000_10.1.e003548.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"issue":"5 Suppl 85","key":"2025100518500764000_10.1.e003548.39","first-page":"S","article-title":"Psoriatic arthritis indices","volume":"32","author":"Schoels","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025100518500764000_10.1.e003548.40","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200305000-00004"},{"key":"2025100518500764000_10.1.e003548.41","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.200410135"},{"key":"2025100518500764000_10.1.e003548.42","doi-asserted-by":"crossref","unstructured":"Hosmer DW , Lemeshow S . Applied logistic regression. In: . 2nd edition. New York: John Wiley & Sons, 13 September 2000. doi:10.1002\/0471722146","DOI":"10.1002\/0471722146"},{"key":"2025100518500764000_10.1.e003548.43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","article-title":"Patient-reported outcomes in Psoriatic arthritis","volume":"42","author":"Orbai","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2025100518500764000_10.1.e003548.44","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000928","article-title":"Fatigue Numeric rating scale validity, discrimination and responder definition in patients with Psoriatic arthritis","volume":"6","author":"Gladman","year":"2020","journal-title":"RMD Open"},{"key":"2025100518500764000_10.1.e003548.45","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000129","article-title":"Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology","volume":"1","author":"de Wit","year":"2015","journal-title":"RMD Open"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T01:50:18Z","timestamp":1759715418000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,31]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/rmdopen-2023-003548"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003548","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}